6OCTOBER 2023TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comEuropean pharmaceutical outsourcing firms have evolved into indispensable partners for drug manufacturers, offering a spectrum of services that span the entire drug development lifecycle, from initial research and development to manufacturing and clinical trials. This sector owes its rapid growth to cost-effectiveness, unwavering adherence to rigorous regulatory standards, and the imperative for specialised domain expertise.These European outsourcing entities are adept at navigating the landscape of stringent quality control and regulatory compliance requirements, ensuring that their products consistently meet and exceed international benchmarks. In research and development, these companies occupy a pivotal role by actively contributing to early-stage drug discovery, conducting essential preclinical testing, and meticulously managing the complexities of clinical trials. With the industry's dynamic nature, it is widely anticipated that these outsourcing firms will continually broaden their service portfolios and embrace transformative digital technologies such as AI and data analytics to remain at the forefront of pharmaceutical innovation.In this edition of Pharma Tech Outlook, we present a select group of pharmaceutical outsourcing companies that offer unparalleled access to an exceptional reservoir of specialised expertise and technologies within niche fields. Among the featured enterprises are Hänseler AG Swiss Pharma, Artemis Bioservices, Richter-Helm BioLogics, and The Native Antigen, all experiencing rapid expansion and are widely recognised as leading sources of reagents for advancing research in emerging diseases. These companies possess a profound understanding of the challenges at hand and are also dedicated to crafting highly effective, tailor-made solutions to meet the unique needs of their clients.The magazine further highlights insights of industry leaders, featuring valuable perspectives from Ivanna M. Rosendal, senior director and IT business partner at Ascendis Pharma; Stefania Alvino, head of digital innovation in the customer experience excellence department at DSPACE, Daiichi Sankyo; and Antti Haapalinna, vice president of external science and partnering in R&D at Orion. These experts share their thoughts and opinions on how pharmaceutical companies actively pursue operational optimization and introduce groundbreaking drugs to the market. We hope these valuable insights from industry leaders featured in this edition will assist you in making informed decisions for your businesses.Let us know your thoughts.European Pharmaceutical Outsourcing: A Driving Force of InnovationCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.OCTOBER - 16 - 2023, Vol 09 - Issue 19 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Edwin PaulTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >